Using molecular biomarkers to guide the choice of therapies for metastatic pancreatic cancer

23:42 EDT 10 Jun 2019 | News-Medical.net

A new pilot study demonstrated the feasibility of using molecular tumor markers as the basis for selecting the chemotherapeutic agents to use in patients with metastatic pancreatic cancer.

More From BioPortfolio on "Using molecular biomarkers to guide the choice of therapies for metastatic pancreatic cancer"